Current status of adoptive immunotherapy of cancer

Critical Reviews in Oncology/Hematology

Volumn 22, Issue 3, 1996, Pages 213-228

  Changa, Alfred E ^a,c   Shu, Suyu ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER IMMUNOTHERAPY; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0029998457     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00194-1     Document Type: Review

References (115)

1. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326-333, 1943.
2. Landsteiner K, Chase MW. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc Soc Exp Biol Med 49:688-690, 1942.
3. Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Biol 143:58-80, 1954.
4. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 102:157-177, 1955.
5. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25:323-388, 1977.
6. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355, 1990.
7. North RJ. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 35:89-155, 1984.
8. Chang AE, Shu S, Chou T et al. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res 46:3426-3430, 1986.
9. Sondak VK, Wagner PD, Shu S et al. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg 126:442-446, 1991.
10. + tumor-infiltrating lymphocytes. J Exp Med 173:647-658, 1991.
11. Schwartzentruber DJ, Hom SS, Dadmarz R et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 12:1475-1483, 1994.
12. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008, 1976.
13. Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin-2. J Immunol 126:1318-1322, 1981.
14. Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin-2. J Exp Med 156:385 397, 1982.
15. Cheever MA, Greenberg PD, Fefer A et al. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J Exp Med 155:968-980, 1982.
16. Donohue JH, Rosenstein M, Chang AE et al. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol 132:2123-2128, 1984.
17. Cheever MA, Greenberg PD, Irle C et al. Interleukin-2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol 132:2259-2265, 1984.
18. Hewitt HB. The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 27:149-200, 1978.
19. Grimm EA, Robb RJ, Roth JA et al. Lymphokine-activated killer cell phenomenon III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158:1356-1361, 1983.
20. Mule JJ, Shu S, Schwarz SL et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487-1489, 1984.
21. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45:3735-3741, 1985.
22. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res 46:4973-4978, 1986.
23. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313:1485-1492, 1985.
24. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316:889-897, 1987.
25. West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med 316:898-905, 1987.
26. Schoof DD, Gramolini BA, Davidson DL et al. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48:5007-5010, 1988.
27. Thompson JA, Lee DJ, Lindgren CG et al. Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine activated killer cells. Cancer Res 49:235-240, 1989.
28. Paciucci PA, Holland JF, Glidewell O et al. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interieukin-2 activated cells in patients with advanced cancer. J Clin Oncol 7:869-878, 1989.
29. Dutcher JP, Creekmore S, Weiss GR et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477-485, 1989.
30. Bar MH, Sznol M, Atkins MB et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 8:1138-1147, 1990.
31. Dutcher JP, Gaynor ER, Boldt DH et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9:641-648, 1991.
32. Wang JCL, Walle A, Novogrodsky A et al. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. J Clin Oncol 7:1885-1891, 1989.
33. Fisher RI, Coltman CA, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial Ann Int Med 108:518-523, 1988.
34. Parkinson DR, Fisher RI, Rayner AA et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8:1630-1636, 1990.
35. Chang AE, Shu S. Immunotherapy with sensitized lymphocytes. Cancer Invest 10:357-369, 1992.
36. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 9:694-704, 1991.
37. Lotze MT, Chang AE, Seipp CA et al. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. J Am Med Assoc 256:3117-3124, 1986.
38. McCabe M, Stablein D, Hawkins MJ. The modified group C experience-phase III randomized trials of IL-2 vs. IL-2/LAK in advanced renal cell cancer and advanced melanoma (Abst. 714). Proc Am Soc Clin Oncol 10:213, 1991.
39. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-632, 1993.
40. Mule JJ, Smith CA, Rosenberg SA. Interleukin-4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med 166:792-797, 1987.
41. Schaub-Owen LB, Gutterman JU, Grimm EA, Synergy of tumor necrosis factor and interleukin-2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor α and interleukin-2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48:788-792, 1988.
42. Ting C-C, Hargrove ME, Yun YS. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J Immunol 141:741-748, 1988.
43. Anderson PM, Blazar BR, Bach FH. Ochoa AC. Anti-CD3+ IL-2 stimulated murine killer cells in vitro generation and in vivo antitumor activity. J Immunol 142:1383-1394, 1989.
44. Curti BD, Longo DL, Ochoa AC et al. Treatment of cancer patients with ex vivo anti-CD3 activated killer cells and interleukin-2. J Clin Oncol 11:652-660, 1994.
45. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RC. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine activated killer cells. Cancer Res 48:3461-3469, 1988.
46. Sasaki A, Melder RJ, Whiteside TL, Herberman RB, Jain RK. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst 83:433-437, 1991.
47. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986.
48. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79:1067-1075, 1987.
49. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142:3714-3725, 1989.
50. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 148:638-643, 1992.
51. Schwartzentruber SJ, Topalian SZ, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumorinfiltrating lymphocytes after autologous tumor stimulation. J Immunol 146:3674-3681, 1991.
52. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 319:1676-1680, 1988.
53. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159-1166, 1994.
54. Kradin RL, Lazarus DS, Dubinett SM et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1:577-580, 1989.
55. Bukowski RM, Sharfman W, Murthy S et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 51:4199-4205, 1991.
56. Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 139:295-304, 1987.
57. Chou T, Chang AE, Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J Immunol 140:2453-2461, 1988.
58. Chou T, Bertera S, Chang AE et al. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 141:1775-1781, 1988.
59. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143:740-748, 1989.
60. Yoshizawa H, Sakai K, Chang AE et al. Activation by antiCD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 134:473-479, 1991.
61. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729-737, 1991.
62. Geiger JD, Wagner PD, Shu S, Chang AE. A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Onc 1:199-208, 1992.
63. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE. Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 13:153-165, 1993.
64. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043-1050, 1993.
65. McCune CS, Marquis DM. Interleukin-1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 50:1212-1215, 1990.
66. Sondak VK, Tuck MK, Shu S, Yoshizawa H, Chang AE. Enhancing effect of interleukin-1α administration on antitumor effector T cell development. Arch Surg 126:1503-1509, 1991.
67. Wagner PD, Shu S, Chang AE. Divergent effects of TNFα in the adoptive immunotherapy of a murine sarcoma. J Surg Res 53:152-157, 1992.
68. Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403, 1990.
69. Asher AL, Mule JJ, Kasid A et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 146:3227-3234, 1991.
70. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820-7825, 1990.
71. Golumbek PT, Lazenby AJ, Levitsky HI et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716, 1991.
72. Colombo MP, Ferrari G, Stoppacciaro A et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173:889-897, 1991.
73. Mullen CA, Coale MM, Levy AT et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 52:6020-6024, 1992.
74. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 177:1127-1134, 1993.
75. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 90:3539-3543, 1993.
76. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 175:1423-1431, 1992.
77. Krauss JC, Strome SE, Chang AE, Shu S. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate IL-4. J Immunother 16:77-84, 1994.
78. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T cell activation. Immunol Today 11:211-216, 1990.
79. + T cells by B7 transfected melanoma cells. Science 259:368-370, 1993.
80. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocytes molecules CD28 and CTLA-4. Cell 71:1093-1102, 1992.
81. Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523-532, 1994.
82. Plautz GE, Yang Z-Y, Wu B-Y, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645-4649, 1993.
83. Wahl WL, Plautz GE, Fox BA et al. Generation of therapeutic T lymphocytes after in vivo transfection of a tumor with a gene encoding allogeneic class 1 major histocompatibility complex antigen. Surg Forum 63:476-478, 1992.
84. Nabel GJ, Nabel EG, Yang Z-Y et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307-11311, 1993.
85. Gao Y, Wu M, Chen H et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263:518-520, 1994.
86. Van Der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991.
87. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719, 1994.
88. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151:1654-1662, 1993.
89. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T cells specific for peptides derived from the HER-2/neu protoncogene protein. Cancer Res 54:1071-1076, 1994.
90. Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 151:5481-5491, 1993.
91. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Association of Her2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393-2400, 1994.
92. Matis LA, Shu S, Groves ES et al. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin-2: correlation with clonal IL-2 receptor expression. J Immunol 136:3496-3501, 1986.
93. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 146:4414-4420, 1991.
94. Massaro AF, Schoof DD, Rubinstein A, Zuber M, Vidal-Leonard FJ, Eberlein TJ. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res 50:2587-2592, 1990.
95. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189-201, 1990.
96. + peripheral blood lymphocytes. J Immunol 149:3278-3289, 1992.
97. 2+ levels. J Immunol 149:3872-3880, 1992.
98. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD. Activation and growth of murine tumor-specific T cells which have in vivo activity with bryostatin 1. Cancer Res 52:548-553, 1992.
99. Bear HD, Tuttle TM. Adoptive immunotherapy with pharmacologically activated T lymphocytes. In: Chang AE, Shu S, eds. Immunotherapy of Cancer with Sensitized T Lymphocytes. R.G. Landes Company, 1994; 35-52.
100. Shu S, Sussman JJ, Chang AE. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T cell reagents. J Immunother 14:279-285, 1993.
101. Shu S, Krinock RA, Matsumura T et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152:1277-1288, 1994.
102. Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2. alpha interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 80:1393-1397, 1988.
103. Vander Woude DL, Wagner PD, Shu S, Chang AE. Enhanced antitumor reactivity of tumor-sensitized T cells by interferon alpha. Arch Surg 126:307-313, 1991.
104. Pierce WC, Figlin RA, Belldegrun AS. Immunotherapy of renal cell carcinoma with sensitized T lymphocytes: the UCLA experience. In: Chang AE, Shu S, eds. Immunotherapy of Cancer with Sensitized T Lymphocytes, R.G. Landes Company, 1994; 155-164.
105. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin-2, and local tumor irradiation. Studies on the mechanisms of action. J Exp Med 171:249-263, 1990.
106. Wahl WL, Sussman JJ, Shu S, Chang AE. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2 activated tumor-draining lymph node cells. J Immunother 15:242-250, 1994.
107. Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New Engl J Med 1990; 323:570-578.
108. 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 73:1731-1737, 1994.
109. Finn OJ, Persons DA, Bendt KM, Pirami L, Ricciardi P. Retroviral transduction of protein kinase C-gamma into cytotoxic T lymphocyte clones leads to immortalization with retention of specific function. J Immunol 146:1099-1103, 1991.
110. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-724, 1993.
111. Hwu P, Shafer GE, Treisman J et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 178:361-366, 1993.
112. Hwu P. The genetic modification of lymphocytes with chimeric antibody/T-cell receptor genes. Cancer Detect Prev 19:101-102, 1995.
113. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369-3373, 1995.
114. Stancovski I, Schindler DG, Waks T. Targeting of T lymphocytes to Neu/Her2 expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577-6582, 1993.
115. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318-4322, 1994.